Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's diseaseMatthieu F. Bastide, Erwan Bézard, Yunmin Ding et al.|Progress in Neurobiology|2015Cited by 472
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?Fares Bassil, Wassilios G. Meissner, Pierre‐Olivier Fernagut et al.|Progress in Neurobiology|2014Cited by 223
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's diseaseLudovico Arcuri, Michele Morari, Riccardo Viaro et al.|Neurobiology of Disease|2016Cited by 29
Alpha-synuclein-induced nigrostriatal degeneration and pramipexole treatment disrupt frontostriatal plasticityMarianne Benoit‐Marand, Pierre‐Olivier Fernagut|Research Square|2024Cited by 0